This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Adult-onset Still Disease성인발병 스틸병 (성인발병 Still병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M06.1 | Special Copayment Reduction: V298 (rare disease)
B. Synonyms—
C. Adult onsetPossibility of first presentation in adulthood: very high — adult-onset Still disease is, by definition, a systemic autoinflammatory disease that first presents in adulthood (mainly after age 16, median approx. 28–35 years). Unlike the pediatric form (systemic juvenile arthritis), it is diagnosed only in adulthood.
1. History

Adult-onset Still disease (AOSD) has high fever, salmon-colored skin rash, arthritis, and pharyngitis as its four main symptoms…

2. Causes

Adult-onset Still disease is classified as an autoinflammatory disease rather than an autoimmune disease…

3. Genetics

Adult-onset Still disease is a complex genetic disease and is not caused by a specific single-gene variant. HLA associations with HLA-B17, B18, B35, DR…

4. General epidemiology

The incidence of adult-onset Still disease is 0.16–0.62 per million population per year, making it a very rare disease. Age of onset shows a bimodal distribution (16–25 years…

5. Pathophysiology

The pathophysiology of adult-onset Still disease is based on dysregulation of innate immune pathways. Infectious or endogenous danger signals (DAMP/PA…

6. Symptoms

The four main symptoms of adult-onset Still disease are ① high fever, ② salmon-colored rash, ③ arthritis, and ④ pharyngitis. High fever: 38.5…

7. Signs

Physical signs of adult-onset Still disease include high fever (38.5°C or higher), salmon-colored evanescent rash accompanying fever, joint swelling and tenderness, pharyngeal redness and swelling, cervical…

8. Screening

Screening for adult-onset Still disease is a process of exclusion of other causes. In patients with fever of unknown origin (FUO) or fever + arthritis…

9. Diagnosis

Adult-onset Still disease is diagnosed by exclusion, and the most widely used criteria are the Yamaguchi criteria (1992). Major criteria…

10. Treatment

Treatment of adult-onset Still disease is individualized according to disease severity and course pattern (self-limited, single recurrent, chronic polyarticular). Nonsteroidal…

11. Prognosis

The course of adult-onset Still disease is broadly divided into three patterns: ① self-limited (monocyclic): remission after a single episode (approx. 20–30% of all cases), ②…

12. Prevention

Prevention in adult-onset Still disease centers on infection prevention and early recognition and treatment of relapses. Patients on immunosuppressive therapy need pneumococcal, influenza, herpes zoster, and B…

13. References10 papers in major international journals.

1. History

Adult-onset Still disease (AOSD) is a rare systemic autoinflammatory disease whose four main symptoms are high fever, salmon-colored skin rash, arthritis, and pharyngitis. The name derives from the British pediatrician George Frederic Still, who first described systemic arthritis in children in 1897; that the same clinical picture also occurs in adults was first established in 1971 when Eric Bywaters described 14 adult patients.

After Bywaters' description, AOSD was recognized as a distinct clinical entity, and the classification criteria proposed by Yamaguchi et al. in 1987 remain the most widely used diagnostic criteria to date. The Yamaguchi criteria consist of 4 major criteria (fever, arthritis, salmon-colored rash, leukocytosis) and 5 minor criteria (pharyngitis, lymphadenopathy, hepatosplenomegaly, liver function abnormalities, negative RF and ANA).

Pathophysiological research has identified ferritin as a key inflammatory biomarker and pathogenic contributor in AOSD. Hyperferritinemia is used for the diagnosis and assessment of activity of AOSD. Since the 2000s, as the roles of IL-1β, IL-18, IL-6, and IL-17 were elucidated, biologics targeting them were introduced, such as anakinra (IL-1RA), canakinumab (anti-IL-1β), and tocilizumab (anti-IL-6R). In particular, anakinra has the most extensive clinical evidence for AOSD treatment and is recommended as the first-line biologic for relapsing refractory AOSD.

2. Causes

Adult-onset Still disease is classified as an autoinflammatory disease rather than an autoimmune disease. Autoantibodies (ANA, RF) are negative, and activation of innate immunity (monocytes, macrophages, neutrophils, NK cells) rather than adaptive immunity (autoreactive T/B cells) is the core pathogenesis. The leading hypothesis for the pathogenic mechanism is that innate immune hyperactivation by infectious triggers (viruses: parvovirus B19, EBV, CMV, rubella; bacteria: Yersinia, Mycoplasma) leads to uncontrolled systemic inflammation in genetically susceptible patients.

IL-1β, IL-18, IL-6, and IL-17 are important as the main inflammatory mediators. IL-1β is secreted in large amounts through NLRP3 inflammasome activation, and IL-18 activates NK cells and T cells to promote IFN-γ secretion. Mutually reinforcing secretion of IL-18 and IFN-γ is central to AOSD and especially to the development of macrophage activation syndrome (MAS/sHLH). Ferritin is not simply a reactant protein but has immunoregulatory functions, and its oversecretion by macrophages and reduced glycosylation (increased hypoglycosylated ferritin fraction) are used as diagnostic markers of AOSD.

3. Genetics

Adult-onset Still disease is a complex genetic disease and is not caused by a specific single-gene variant. HLA associations with HLA-B17, B18, B35, DR2, DR5, DQ1, and others have been reported in some populations, but the strength of association is weak. Some studies have linked promoter polymorphisms of the IL-18 gene (11q22.2) to AOSD risk. Variants in the fever-related NLRP3 and IL1RN genes are rare but have been reported in some patients with an AOSD-like phenotype. Familial clustering is extremely rare, and the clinical significance of genetic counseling is limited. Gene panels (autoinflammatory gene panels) are used in patients with atypical presentation or when pediatric onset is suspected, to exclude monogenic autoinflammatory diseases.

4. General epidemiology

The incidence of adult-onset Still disease is 0.16–0.62 per million population per year, making it a very rare disease. Age of onset shows a bimodal distribution (16–25 years and 36–46 years), with a median of 28–35 years. There is no sex difference or a slight female predominance. It occurs in all races worldwide, but HLA association patterns may differ in East Asian populations. In Korea, it is registered as a rare disease, and Special Copayment Reduction V298 applies. Systemic juvenile idiopathic arthritis (sJIA) and AOSD likely belong to the same disease spectrum, differing only in age-dependent phenotype, and IL-1β and IL-18 are central to the pathogenesis of both. Progression to macrophage activation syndrome (MAS) is the most dangerous complication of AOSD and a major cause of morbidity and mortality.

5. Pathophysiology

The pathophysiology of adult-onset Still disease is based on dysregulation of innate immune pathways. Infectious or endogenous danger signals (DAMP/PAMP) activate the NLRP3 inflammasome in monocytes and macrophages, resulting in massive secretion of IL-1β and IL-18. IL-18 induces IFN-γ secretion by NK cells and CD8+ T cells, and IFN-γ activates macrophages to induce further IL-18 secretion, forming a positive feedback loop. Dysregulation of this loop is the mechanism of progression to macrophage activation syndrome (MAS).

IL-6 induces the acute-phase response (fever, elevated CRP and ferritin), and IL-17 contributes to skin rash and some arthritis symptoms. Ferritin has immunoregulatory functions in that H-chain ferritin suppresses Th1 immunity and impairs regulatory T-cell function, and in AOSD the ferritin glycosylation ratio is low, making this function even more important. A hypoglycosylated ferritin fraction (≤20%) has been proposed as a biomarker specific to AOSD.

6. Symptoms

The four main symptoms of adult-onset Still disease are ① high fever, ② salmon-colored rash, ③ arthritis, and ④ pharyngitis. High fever: daily or alternate-day fever of 38.5°C or higher persisting for several weeks or longer, characteristically with a spike pattern once or twice in the afternoon to evening. Defervescence is accompanied by sweating and temporary improvement in general condition. Salmon-colored rash: a pink-to-salmon, nonpruritic maculopapular rash on the trunk and limbs that appears with fever and disappears with defervescence (evanescent). This feature is the clinical diagnostic clue to the AOSD rash.

Arthritis: polyarticular or oligoarticular arthritis, mainly of the wrists, knees, ankles, elbows, and finger and toe joints. Pharyngitis: characterized by nonsuppurative (nongranulomatous) pharyngeal redness, pain, and dysphagia. Lymphadenopathy (cervical, axillary, inguinal), hepatosplenomegaly, serosal effusions (pleuritis, pericarditis), and liver function abnormalities (elevated ALT, AST) may also be present. If macrophage activation syndrome (MAS/sHLH) develops as a complication, persistent high fever, pancytopenia, rapid deterioration of liver function, coagulopathy, and altered consciousness appear and are life-threatening.

7. Signs

Characteristic physical signs of adult-onset Still disease include high fever (38.5°C or higher), salmon-colored evanescent rash accompanying fever, joint swelling and tenderness, pharyngeal redness and swelling, cervical lymphadenopathy, and hepatosplenomegaly. The rash is mainly observed on the trunk, and teaching patients to photograph the rash during high fever aids diagnosis. Among laboratory findings, hyperferritinemia (5 or more times the upper limit of normal; usually 1,000 ng/mL or higher is the diagnostic reference value, tens of thousands of ng/mL in severe cases) is the most characteristic. It is accompanied by leukocytosis (10,000/μL or higher, mainly neutrophilia), thrombocytosis or thrombocytopenia (with progression to MAS), markedly elevated CRP and ESR, elevated ALT and AST, and hypoalbuminemia. ANA and RF are typically negative. With progression to MAS, a sharp drop in platelets, decreased fibrinogen, increased D-dimer, and a sharp rise in sCD25 (IL-2 receptor) appear.

8. Screening

Screening for adult-onset Still disease is a process of exclusion of other causes. AOSD must be considered in the differential diagnosis of patients with fever of unknown origin (FUO) or fever + arthritis. Main screening tests: ① complete blood count (CBC), ② serum ferritin (hyperferritinemia), ③ ferritin glycosylation ratio, ④ CRP, ESR, ⑤ LFT (liver function), ⑥ ANA, RF (confirming negativity), ⑦ blood cultures and infection markers. Extensive testing is needed to exclude malignancy, infection, and other rheumatic diseases. Imaging (chest X-ray, abdominal CT, joint ultrasound, FDG-PET) is used for differential diagnosis and assessment of disease extent.

9. Diagnosis

Adult-onset Still disease is diagnosed by exclusion, and the most widely used criteria are the Yamaguchi criteria (1992). 4 major criteria: ① fever of 38.5°C or higher (1 week or longer), ② arthralgia/arthritis (2 weeks or longer), ③ typical rash, ④ leukocytosis (10,000/μL or higher, neutrophils 80% or higher). 5 minor criteria: ① sore throat, ② lymphadenopathy, ③ hepatosplenomegaly, ④ liver function abnormalities, ⑤ negative RF and ANA. Diagnosis is made when 5 or more major criteria, or 2 or more major plus 3 or more minor criteria, are met. The Fautrel criteria (2002) increased sensitivity by including the ferritin glycosylation fraction. Importantly, the diagnosis is made only after infection, malignancy, and other autoimmune diseases have been excluded.

10. Treatment

Treatment of adult-onset Still disease is individualized according to disease severity and course pattern (self-limited, single recurrent, chronic polyarticular). Nonsteroidal anti-inflammatory drugs (NSAIDs) are used as initial treatment for mild fever and arthralgia, but are sufficient alone in only 20–25% of cases. Systemic corticosteroids: in moderate to severe disease, start prednisolone 0.5–1 mg/kg/day and taper gradually. If the steroid response is insufficient or the patient becomes steroid-dependent, switch to a DMARD or biologic. Methotrexate: used in the chronic arthritis form for steroid sparing and prevention of joint damage. Anakinra: an IL-1 receptor antagonist; the first-line biologic for steroid-refractory AOSD and also effective for preventing and treating MAS. Canakinumab: an anti-IL-1β monoclonal antibody, used to maintain long-term remission. Tocilizumab: an anti-IL-6R antibody, effective particularly in patients who fail IL-1 blockade. With progression to MAS, an HLH protocol including high-dose steroids, cyclosporine, and etoposide is applied.

11. Prognosis

The course of adult-onset Still disease is broadly divided into three patterns: ① self-limited (monocyclic): remission after a single episode (approx. 20–30% of all cases), ② relapsing (polycyclic): alternating recurrent episodes and remissions (approx. 30–40%), ③ chronic polyarticular (chronic articular): persistent progression of arthritis (approx. 30–40%). The most important cause of death is macrophage activation syndrome (MAS), which occurs in approximately 10–15% of AOSD patients with a mortality rate of approximately 20–30%. The introduction of biologics (anakinra, canakinumab, tocilizumab) has been shown to reduce steroid dependence, improve remission rates, and prevent MAS. Poor prognostic factors: chronic arthritis form, recurrent MAS, long-term high-dose steroid use, cardiopulmonary serosal complications. Regular follow-up (ferritin, CBC, LFT, joint function assessment) is essential for early detection of relapse.

12. Prevention

Prevention in adult-onset Still disease centers on infection prevention and early recognition and treatment of relapses. Patients on immunosuppressive therapy need pneumococcal, influenza, herpes zoster, and hepatitis B vaccinations, and live vaccines should be avoided. Patients need to be taught to contact their physician immediately when fever spikes and salmon-colored rash appear. Regular monitoring for early signs of MAS (sharp drop in platelets, sharp rise in ferritin, worsening liver function) is essential. In patients on long-term steroids, osteoporosis prevention, blood glucose monitoring, and infection prevention are needed. Long-term maintenance therapy with anakinra or canakinumab can reduce relapse frequency and MAS risk, and regular follow-up is needed to assess the efficacy and safety of biologics.

13. References

  1. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19(3):424-430. PMID: 1578458.
  2. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol. 2018;14(10):603-618. DOI: 10.1038/s41584-018-0081-x. PMID: 30209404.
  3. Bagnari V, Colina M, Ciancio G, Govoni M, Trotta F. Adult-onset Still's disease. Rheumatol Int. 2010;30(7):855-862. DOI: 10.1007/s00296-009-1291-y. PMID: 20082097.
  4. Mavragani CP, Spyridakis EG, Koutsilieris M. Adult-onset Still's disease: from pathophysiology to targeted therapies. Int J Inflam. 2012;2012:879020. DOI: 10.1155/2012/879020. PMID: 22701799.
  5. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22(5):773-792. DOI: 10.1016/j.berh.2008.08.006. PMID: 19028365.
  6. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis. 2006;65(5):564-572. DOI: 10.1136/ard.2005.042143. PMID: 16219707.
  7. Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, Sève P. Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. Immunol Res. 2015;61(1-2):53-62. DOI: 10.1007/s12026-014-8561-9. PMID: 25252680.
  8. Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res. 2013;65(5):822-826. DOI: 10.1002/acr.21901. PMID: 23281260.
  9. Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14(1):194. DOI: 10.1186/s12916-016-0738-8. PMID: 27927218.
  10. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still's disease. Autoimmun Rev. 2014;13(7):708-722. DOI: 10.1016/j.autrev.2014.01.058. PMID: 24657513.